Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos. Cytokinetics has won FDA approval of its ...

"This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...

A PaO2 test measures oxygen pressure in arterial blood to help guide treatment for respiratory issues. This test is part of an arterial blood gas (ABG) test, which also measures other components like ...

At 1 year after participants’ ICU stay for acute respiratory failure, mean DLCO was about 5% lower in those who had an ICU oxygenation target of 60 vs 90 mm Hg. Cognitive impairment levels among ...

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...

During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...

(RTTNews) - Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ...

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy The full results from ...